A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Adults With Stage I, II, or III Mycosis Fungoides (Cutaneous T-Cell Lymphoma, CTCL)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs WP 1220 (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions; Proof of concept
- Sponsors Moleculin Biotech
- 18 Feb 2020 Results presented in the Moleculin Biotech Media Release.
- 18 Feb 2020 According to a Moleculin Biotech media release, final data from this trial were published and presented by Dr. M. Sokolowska-Wojdylo in conjunction at the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona, Spain on February 13, 2020.
- 19 Nov 2019 Results presented in Moleculin Biotech Media Release.